公开(公告)号：US20220073880A1

公开(公告)日：2022-03-10

申请号：US17255091

申请日：2019-06-26

Applicant: IMPERIAL COLLEGE INNOVATIONS LIMITED

Inventor： Matthew J. FUCHTER ,  Amaia Uriz HUARTE ,  Hugh J.M. BRADY

IPC: C12N5/0783 ,  A61K35/17 ,  C07D217/26 ,  C07D413/06 ,  C07D417/06 ,  C07D409/06 ,  C07D405/06

Abstract: This invention relates to Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to the expansion of IMK cells by increasing the expression of specific transcription factors associated with NK cell production.

公开(公告)号：US11229637B2

公开(公告)日：2022-01-25

申请号：US16818800

申请日：2020-03-13

Applicant: FibroGen, Inc.

Inventor： Michael P. Arend ,  Lee A. Flippin ,  Volkmar Guenzler-Pukall ,  Wen-Bin Ho ,  Eric D. Turtle ,  Xiaohui Du

IPC: A61K31/472 ,  A61K31/473 ,  C07D221/08 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D217/26 ,  A61K38/18 ,  A61K31/4725 ,  C07D217/24

Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.

公开(公告)号：US20210078938A1

公开(公告)日：2021-03-18

申请号：US17108739

申请日：2020-12-01

Applicant: City of Hope

Inventor： Linda H. Malkas ,  David Horne ,  Robert J. Hickey ,  Long Gu

IPC: C07C233/76 ,  A61K33/24 ,  C07D213/68 ,  A61K31/4725 ,  A61K31/4418 ,  C07D401/12 ,  C07D217/26 ,  C07C237/22 ,  A61P35/02 ,  A61P35/00 ,  A61K31/167 ,  A61K31/4409

Abstract: Described herein, inter alia, are compositions of PCNA modulators and methods for treating or preventing cancer.

公开(公告)号：US20210060000A1

公开(公告)日：2021-03-04

申请号：US16818800

申请日：2020-03-13

Applicant: FibroGen, Inc.

Inventor： Michael P. Arend ,  Lee A. Flippin ,  Volkmar Guenzler-Pukall ,  Wen-Bin Ho ,  Eric D. Turtle ,  Xiaohui Du

IPC: A61K31/472 ,  C07D221/08 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D217/26 ,  A61K38/18 ,  A61K31/4725 ,  A61K31/473

Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-assocaited conditions by increasing endogenous erythropoietin in vitro and in vivo.

公开(公告)号：US20210053991A1

公开(公告)日：2021-02-25

申请号：US16960192

申请日：2019-01-14

Applicant: BASF SE

Inventor： Michael Rack ,  Bernd Mueller

IPC: C07F1/02 ,  C07D213/61 ,  C07D217/26 ,  C07D401/04

Abstract: The present invention relates to a process for the preparation pyridine derivatives of the formula (I).

公开(公告)号：US20200345727A1

公开(公告)日：2020-11-05

申请号：US16761390

申请日：2018-11-02

Applicant: Calico Life Sciences LLC ,  AbbVie Inc.

Inventor： Kathleen Ann Martin ,  Carmela Sidrauski ,  Jennifer M. Frost ,  Marina Pliushchev ,  Yunsong Tong ,  Lawrence A. Black ,  Xiangdong Xu ,  Lei Shi ,  Qingwei I. Zhang ,  SeungWon Chung ,  Ramzi Farah Sweis ,  Michael J. Dart ,  John T. Randolph ,  Kathleen J. Murauski

IPC: A61K31/4965 ,  A61K45/06 ,  C07D261/18 ,  C07D263/34 ,  C07D241/20 ,  A61K31/421 ,  A61K31/42 ,  A61K31/437 ,  C07D471/04 ,  C07D487/04 ,  C07D333/38 ,  C07D307/68 ,  A61K31/381 ,  A61K31/519 ,  A61K31/341 ,  A61K31/415 ,  A61K31/426 ,  A61K31/425 ,  C07D275/03 ,  C07D277/56 ,  C07D231/14 ,  C07D495/04 ,  A61K31/4985 ,  C07D237/20 ,  C07D413/04 ,  C07D285/06 ,  C07D317/46 ,  A61K31/36 ,  A61K31/4245 ,  A61K31/422 ,  A61K31/4196 ,  C07D249/10 ,  C07D217/26 ,  A61K31/472 ,  A61K31/196 ,  C07C233/62 ,  C07D401/04 ,  A61K31/4427 ,  A61K31/5355

Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

公开(公告)号：US20200345700A1

公开(公告)日：2020-11-05

申请号：US16479602

申请日：2018-01-24

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Lingyun WU ,  Li ZHANG ,  Lele ZHAO ,  Jianjun SUN ,  Zhaoguo CHEN ,  Jian Ll ,  Shuhui CHEN

IPC: A61K31/4245 ,  A61K33/243 ,  A61P35/00 ,  A61K31/277 ,  C07C255/46 ,  C07D257/04 ,  A61K31/41 ,  A61K31/135 ,  C07C211/40 ,  C07D207/335 ,  A61K31/40 ,  C07D207/09 ,  C07D233/64 ,  A61K31/417 ,  A61K31/4196 ,  C07D249/08 ,  C07D213/38 ,  A61K31/44 ,  A61K31/426 ,  C07D277/28 ,  C07D487/04 ,  A61K31/4188 ,  C07D271/06 ,  A61K31/165 ,  C07C233/58 ,  C07D413/04 ,  A61K31/4439 ,  A61K31/437 ,  C07D471/04 ,  C07D263/56 ,  A61K31/423 ,  A61K31/4375 ,  C07D217/26 ,  A61K31/472 ,  A61K31/451 ,  C07D211/18 ,  C07D211/34 ,  C07D209/44 ,  A61K31/4035 ,  A61K31/55 ,  C07D223/16 ,  C07D261/20 ,  A61K31/519 ,  C07D413/10 ,  C07D417/04 ,  A61K31/428 ,  A61K31/4192 ,  C07D249/06 ,  A61K31/4545 ,  C07D413/14 ,  A61K31/415 ,  C07D231/12 ,  C07D413/06 ,  A61K31/422

Abstract: A cyclopropylamine compound as a lysine-specific demethylase 1 (LSD1) inhibitor. Particularly, the present invention relates to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The present invention also provides an application of the same in preparing a drug for treating an LSD1-related disease.

公开(公告)号：US20200270266A1

公开(公告)日：2020-08-27

申请号：US16871532

申请日：2020-05-11

Applicant: Astellas Pharma Inc. ,  Cytokinetics, Incorporated

Inventor： Ippei SATO ,  Takashi KAMIKUBO ,  Masanori MIURA ,  Yuji MATSUSHIMA ,  Hiroaki TANAKA ,  Yasuhiro SHIINA ,  Susumu YAMAKI ,  Tomoyuki SAITO ,  Hiroshi KIYOHARA ,  Munemichi OHE ,  Kayoko MIHARA ,  Bradley Paul MORGAN ,  Fady MALIK ,  Scott Emile COLLIBEE ,  Luke ASHCRAFT ,  Pu-Ping LU ,  Jeffrey Michael WARRINGTON ,  Marc GARARD

IPC: C07D491/20 ,  C07D491/107 ,  C07D217/24 ,  C07D471/04 ,  C07D217/26 ,  C07D471/10 ,  A61P21/00

Abstract: Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

公开(公告)号：US20200247753A1

公开(公告)日：2020-08-06

申请号：US16637452

申请日：2018-08-10

Applicant: DR. REDDY'S LABORATORIES LIMITED

Inventor： Divya Jyothi KALLEM ,  Rajesh THIPPARABOINA ,  Deepika PATHIVADA ,  Vishweshwar PEDDY ,  Shanmukha Prasad GOPI

IPC: C07D217/26 ,  C07D207/16 ,  C07D213/82 ,  C07C275/02

Abstract: The present invention provides crystalline Roxadustat Form-γ, crystalline Roxadustat Form-δ, process for the preparation of crystalline Roxadustat Form-γ, crystalline Roxadustat Form-δ and its pharmaceutical compositions thereof. The present invention also provides co-crystals of Roxadustat Form RLP, Roxadustat Form RNM and Roxadustat Form RU, process for their preparation and pharmaceutical composition thereof.

公开(公告)号：US20200216396A1

公开(公告)日：2020-07-09

申请号：US16734102

申请日：2020-01-03

Applicant: Sojournix, Inc.

Inventor： David J. Turnquist ,  Jayachandra P. Reddy ,  Philip B. Graham

IPC: C07D217/26 ,  A61K9/70

Abstract: Disclosed herein are deuterated forms of 2-ethylamino-8-fluoro-3-methyl-1-oxo-1,2-dihydro-isoquinoline-4-carboxylic acid ((S)-cyclopropyl-phenyl-methyl)-amide (also referred to herein as SJB-01) and pharmaceutical compositions comprising such compounds.